"Commonly Used H1 and H2 Histamine Receptor (HR) Blockers Decrease Chol" by Lindsey Kennedy, Laura Hargrove et al.

Menu

Skip to main content

Hepatobiliary Cancers: Pathobiology and Translational Advances

Commonly Used H1 and H2 Histamine Receptor (HR) Blockers Decrease Cholangiocarcinoma Xenograft Tumor Growth, Angiogenesis and EMT

Lindsey Kennedy, Texas A & M University System Health Science CenterFollow
Laura Hargrove, The Texas A & M University System Health Science Center
Jennifer Demieville, Central Texas Veterans Research Foundation
Walker Karstens, Baylor Scott & White Health
Steven Smith, Baylor Scott & White Health
Heather Francis, The Texas A & M University System Health Science CenterFollow

Document Type

Abstract Accepted for Presentation

Date

2017

Date of Submission

June 2017

Rights

© The Author(s)

Is Part Of

Hepatobiliary Cancers: Pathobiology and Translational Advances

Included in

Cell Biology Commons, Digestive, Oral, and Skin Physiology Commons, Digestive System Diseases Commons

COinS

Virginia Commonwealth University is a nationally renowned public research institution dedicated to the success and well-being of all members of its community. VCU student, faculty and staff groups and associations are open without regard to any characteristic or identity protected by law.